Join our teams!
We do everything possible for all Group employees to have the means to succeed, to adapt, to take on responsibilities and to grow. At Servier, you will be offered a unique and meaningful professional experience.
Servier - Independent international pharmaceutical laboratory
21800
employees
150
countries in which
the Group’s medicines
are distributed
+ 20 %
of the brand-name revenue
in R&D every year
€ 4.7 billion
euros in revenue in 2020/2021 comprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines.
4 therapeutic areas
oncology,
cardiometabolism, neuroscience
and immuno-inflammation
Cholangiocarcinoma, a rare tumor of the bile duct
Cholangiocarcinoma, also known as bile duct cancer, is a rare and aggressive tumor. It is often associated with medical antecedents such as cirrhosis or infections of the liver. Surgery is the only treatment to cure this form of cancer. Developments in immunotherapy and new targeted drug therapies bring greater hope and better quality of life for patients.
2022 Greetings
Servier wishes you a healthy and prosperous new year 2022.
The basis for our actions
Because passing on to future generations a world that can ensure access to quality health care for all is our vision for the future, at Servier, all over the world, we are ready to meet the health care challenges of tomorrow, for and with patients. Discover our corporate video.
